EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation

Irene Graf iD, Philipp Wohlfarth, Michael Kundi iD, Margit Mitterbauer, Axel Schulenburg, Alexander W Hauswirth, Karoline V Gleixner, Hanna A Knaus, Lina Z Rüsing iD, Werner Rabitsch, Peter Valent iD, Wolfgang R Sperr

Cancers · 09.11.2026 · 18 (21) · 3593

DOI: 10.3390/cancers18213593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 09.11.2026. Verfasst von Irene Graf und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer (Germany).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative option for patients with drug-refractory acute myeloid (AML) or acute lymphoblastic leukemia (ALL). Patients and Methods: We retrospectively analyzed 82 patients (median age 47.5 years, range 19–69; female:male ratio 1:1.28) with drug-refractory (R) or relapsed/refractory (RR) acute leukemia (AML n = 66; ALL n = 16) who were treated with clofarabine (10 mg/m2) and cyclophosphamide (200 mg/m2) days 1–4 (ClofCy) prior to HSCT.

Results

ClofCy resulted in rapid cytoreduction (median time to granulocytes

Schlagwörter

Stichwörter der Autor:innen

ALLAMLbridging therapyclofarabinecyclophosphamidehematopoietic stem cell transplantationrefractory leukemiarelapsed/refractory leukemia

Autor:innen und Institutionen

  • Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
  • Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
  • Bone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
  • Center for Public Health, Department of Environmental Health, Medical University of Vienna, 1090 Vienna, Austria.

ORCID-Profile: Irene Graf, Michael Kundi, Lina Z Rüsing, Peter Valent

Förderung

  • Pfizer (Germany)

Zitieren

APA

Graf, I., Wohlfarth, P., Kundi, M., Mitterbauer, M., Schulenburg, A., Hauswirth, A. W., Gleixner, K. V., Knaus, H. A., Rüsing, L. Z., Rabitsch, W., Valent, P., & Sperr, W. R. (2026). Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation. Cancers, 18(21), 3593. https://doi.org/10.3390/cancers18213593

Vancouver

Graf I, Wohlfarth P, Kundi M, Mitterbauer M, Schulenburg A, Hauswirth AW, et al. Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation. Cancers. 2026;18(21):3593. doi:10.3390/cancers18213593

BibTeX
@article{Graf2026,
  author = {Graf, Irene and Wohlfarth, Philipp and Kundi, Michael and Mitterbauer, Margit and Schulenburg, Axel and Hauswirth, Alexander W and Gleixner, Karoline V and Knaus, Hanna A and Rüsing, Lina Z and Rabitsch, Werner and Valent, Peter and Sperr, Wolfgang R},
  title = {Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3593},
  doi = {10.3390/cancers18213593}
}
Kostenlos starten →